Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
COVID-19
NITAG documentation
Adults
Risk group
Clear all
Type of publications
NITAG documentation
(8)
Systematic reviews (SYSVAC)
(467)
Topics
Background paper
(2)
Recommendation
(6)
Regions
Americas
(4)
Europe
(3)
Western Pacific
(1)
Countries
Australia
(1)
Belgium
(1)
Canada
(1)
Chile
(1)
France
(1)
United Kingdom
(1)
United States of America
(2)
Diseases
COVID-19
(8)
Hepatitis A
(1)
Hepatitis B
(1)
Herpes zoster
(2)
Human papillomavirus (HPV)
(2)
Influenza
(2)
Japanese encephalitis
(2)
Meningococcal disease
(1)
Mumps
(1)
Pertussis
(1)
Pneumococcal disease
(5)
Rabies
(1)
Publication date
2021
(5)
2020
(3)
Target population
Adults
(3)
Risk group
(5)
Adolescents
(2)
Healthcare workers
(4)
Newborn
(1)
Older adults
(4)
Pregnant women
(5)
Available to download in languages
English (EN)
(4)
French (FR)
(2)
Spanish (ES)
(1)
8 results found
2021
∙
ATAGI
ATAGI statement on AstraZeneca vaccine in response to new vaccine safety concerns - 8 April, 2021
2021
∙
NACI
NACI rapid response: Recommended use of AstraZeneca COVID-19 vaccine in younger adults
2021
∙
JCVI
New COVID-19 vaccine advice for adults living with adults who are immunosuppressed
2021
∙
Conseil Supérieur de la Santé (CSS)
Non-replicating viral vector vaccines and the Belgian COVID-19 vaccination strategy
2021
∙
Haute Autorité de Santé
Update of risk factors for severe forms of Covid-19 and recommendations on the strategy for prioritizing populations to be vaccinated
2020
∙
CAVEI
CAVEI provisional recommendation for the initial prioritization of groups to be vaccinated against SARS-CoV-2 in the context of limited supply
2020
∙
ACIP
COVID-19 vaccine prioritization: Work Group considerations
2020
∙
ACIP, Nancy McClung
Epidemiology of Individuals at Increased Risk of COVID-19 Disease
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register